COVID-  19 pandemic and health care disparities in head and neck cancer: Scanning the horizon by Graboyes, Evan et al.
S P E C I A L I S S U E
COVID-19 pandemic and health care disparities in head and
neck cancer: Scanning the horizon
Evan Graboyes MD, MPH1 | John Cramer MD2 | Karthik Balakrishnan MD3 |
David M. Cognetti MD4 | Daniel López-Cevallos PhD, MPH5 |
John R. de Almeida MD, MSc6 | Uchechukwu C. Megwalu MD, MPH3 |
Charles E. Moore MD7 | Cherie-Ann Nathan MD8 |
Matthew E. Spector MD9 | Carol M. Lewis MD, MPH10 | Michael J. Brenner MD9
1Department of Otolaryngology-Head & Neck Surgery, Medical University of South Carolina, Charleston, South Carolina
2Department of Otolaryngology-Head & Neck Surgery, Wayne State University, Detroit, Michigan
3Department of Otolaryngology-Head & Neck Surgery, Stanford University, Stanford, California
4Department of Otolaryngology-Head & Neck Surgery, Thomas Jefferson University, Philadelphia, Pennsylvania
5School of Language, Culture & Society, Oregon State University, Corvallis, Oregon
6University Health Network/ Princess Margaret Cancer Centre, University of Toronto, Toronto, Ontario
7Department of Otolaryngology-Head & Neck Surgery, Emory University, Atlanta, Georgia
8Department of Otolaryngology-Head & Neck Surgery, Louisiana State University Health Sciences Center, Shreveport, Louisiana
9Department of Otolaryngology-Head & Neck Surgery, University of Michigan, Ann Arbor, Michigan
10Head & Neck Surgery, University of Texas MD Anderson Cancer Center, Houston, Texas
Correspondence
Michael J. Brenner, MD, Department of
Otolaryngology-Head and Neck Surgery,
University of Michigan, 1500 East Medical
Center Drive, SPC 5312, 1904 Taubman
Center, Ann Arbor, MI 48109-5312.
Email: mbren@med.umich.edu
Funding information
Doris Duke Charitable Foundation,
Grant/Award Number: DDCF2015209;
National Cancer Institute, Grant/Award
Number: K08CA237858
Abstract
The COVID-19 pandemic has profoundly disrupted head and neck cancer
(HNC) care delivery in ways that will likely persist long term. As we scan the
horizon, this crisis has the potential to amplify preexisting racial/ethnic dispar-
ities for patients with HNC. Potential drivers of disparate HNC survival
resulting from the pandemic include (a) differential access to telemedicine,
timely diagnosis, and treatment; (b) implicit bias in initiatives to triage, priori-
tize, and schedule HNC-directed therapy; and (c) the marked changes in
employment, health insurance, and dependent care. We present four strategies
to mitigate these disparities: (a) collect detailed data on access to care by race/
ethnicity, income, education, and community; (b) raise awareness of HNC dis-
parities; (c) engage stakeholders in developing culturally appropriate solutions;
and (d) ensure that surgical prioritization protocols minimize risk of racial/ethnic
bias. Collectively, these measures address social determinants of health and
the moral imperative to provide equitable, high-quality HNC care.
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1 | INTRODUCTION
The COVID-19 pandemic due to SARS-CoV-2 (severe
acute respiratory syndrome coronavirus 2) has disrupted
and transformed the delivery of health care in ways that
few would have imagined or thought possible. Clinicians,
health care administrators, insurance companies, policy
makers, researchers, and patients are all grappling with
how to deliver and access medical care in the COVID-19
era while planning for an unpredictable future contin-
gent on several unknowns (eg, viral seasonality, vaccine
development). The various stakeholders are charting a
course for health care delivery during a time of unprece-
dented resource scarcity, relatively uncertain but poten-
tially significant personal risk (for clinicians and
patients), and massive economic upheaval. In response to
the COVID-19 pandemic, best practices in health care
delivery for head and neck cancer (HNC) have been
upended amid urgent efforts to protect patients, pro-
viders, and communities while stewarding scarce
resources.
As the pandemic has unfolded across the world, it has
become increasingly clear that COVID-19 is a disease
with varying incidence and mortality in racial/ethnic
subgroups.1,2 Although the causes for COVID-19-related
racial and ethnic differences are still being examined,
they seem to stem from (a) long-standing systemic ineq-
uities and differences in social determinants of health,
access to care, and quality of care and (b) biologic deter-
minants such as comorbidity burden, genetics, and
immune phenotype.3-5 COVID-19 reminds us that deter-
minants of health are multifactorial. Thought leaders in
global public health have recently called for development
of polysocial risk scores, adapted from the polygenic risk
modeling to quantify social determinants of health.6 In
that sense, the COVID-19 pandemic has been described
as a magnifying glass that has brought attention yet again
to stark racial/ethnic disparities in health outcomes in
the United States.3
We have long recognized that HNC is a disease with
marked racial/ethnic disparities in outcomes.7-11
Although the reasons underlying observed racial/ethnic
differences in mortality for patients with HNC are multi-
factorial, disparities in both access to care and timely can-
cer care are major drivers for poor outcomes.8,11-15
Although the calls to view health care delivery as science
that informs national improvement priorities are not
new,16 the disruptive forces of the COVID-19 pandemic
regarding crisis standards of care (CSC) are unprece-
dented. It is imperative that we consider how COVID-19-
related changes to health care delivery exacerbate
existing disparities in access to care and may worsen
oncologic outcomes for patients with HNC. Many health
care system changes attributable to COVID-19 will likely
persist long after the pandemic has waned.17 We must
explore strategies to mitigate disparities in care for
patients with HNC that have arisen from this “stress test”
on our health care delivery system.
2 | IMPACT OF COVID-19 ON THE
EQUITY OF CANCER CARE
DELIVERY FOR PATIENTS
WITH HNC
First, COVID-19-associated changes in health care deliv-
ery may widen the existing disparities in timely diagnosis
and treatment of HNC as a result of reduced access to
health care providers. For patients with HNC, access to
and receipt of timely treatment across the cancer care
continuum is critical to optimal oncologic outcomes.18,19
It is therefore not surprising that racial and ethnic differ-
ences in timely treatment are strongly associated with
racial and ethnic differences in oncologic outcomes.8,11-15
Care during the COVID-19 pandemic has brought about
an abrupt and precipitous reduction in the number of
patients accessing HNC-related care.20 There has also
been an associated transformation in the method of care
delivery for patients with HNC, with a shift toward tele-
medicine in lieu of in-person consultation and follow-
up.20,21 However, access to telehealth is a privilege not
shared by all.22 Studies across a variety of disease states
have demonstrated that telehealth-based interventions
are neither culturally appropriate nor tailored which may
result in low uptake among African American and His-
panic/Latino communities, exacerbating disparities in
access.23 The specific financial, structural, and institu-
tional characteristics of health care systems that affect
racial and ethnic differences in care also require atten-
tion. The hospitals where African Americans, Hispanic/
Latino, and other racial/ethnic minorities tend to seek
care are often less likely to have the resources and may
have less capacity for a comprehensive telehealth pro-
gram, further creating a divide.24 Many telehealth plat-
forms require the use of electronic devices with certain
software requirements, which may not be readily avail-
able to low-income and racial/ethnic minority patients.25
Furthermore, access to telehealth may also be limited by
inadequate health literacy and low English proficiency,
which may be more prevalent in these populations.26
Second, ongoing initiatives to triage, prioritize, and
schedule HNC-directed therapy to accommodate scarce
resources during the COVID-19 pandemic may exacer-
bate preexisting racial/ethnic disparities in timely treat-
ment initiation. The considerations mirror national
discourse on CSC that modify health care operations and
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preferentially triage lifesaving resources based on likeli-
hood of survival. The latent threat to minorities in CSC is
that when comorbidities are used in prioritization
schemes a proxy for health, minority patients who, in
general, have higher base rates of comorbidities (and
increased risk of mortality) may be deprioritized for
access, placing them in double jeopardy.27 Although risk
stratification protocols have been developed to maximize
objectivity in determining treatment priority,28 the risk of
bias, implicit or explicit, looms large.29
Third, the marked changes in employment status,
health insurance coverage, and dependent care responsi-
bilities may further aggravate racial/ethnic disparities in
access to care and treatment for patients with HNC, par-
ticularly because workers of color are more likely to have
lost employment during the pandemic.30 According to
the US Census, over 36 million Americans have already
filed unemployment claims as of May 14, 2020. Prior to
the COVID-19 pandemic, insurance coverage was
strongly linked to stage at diagnosis, timely treatment ini-
tiation, and oncologic outcomes.31,32 The abrupt loss of
insurance coverage for vulnerable patients, compounded
by the financial shock of having to absorb the out-of-
pocket costs of care, will certainly worsen racial dispar-
ities in access to multidisciplinary HNC care. In addition,
the increased need for childcare due to school closings
during the COVID-19 pandemic may introduce another
barrier to seeking care that disproportionately burdens
racial and ethnic minorities.
3 | STRATEGIES TO ADDRESS
WORSENING HNC CARE
DISPARITIES DURING THE COVID-
19 PANDEMIC
Although the COVID-19 crisis has shone a light on
already-marked disparities, it has also provided an impe-
tus for structural changes that can mitigate inequities in
access and outcomes both in times of pandemic and
beyond. We offer the following suggestions.
3.1 | Collect detailed data on access to
care by race/ethnicity, income, education,
and community
It is imperative that we collect data about HNC care deliv-
ery and access to care in a manner that allows us to more
comprehensively examine racial and ethnic disparities as
well as the underlying social determinants of health. Oto-
laryngology-head and neck surgery groups analyzing the
impact of COVID-19 on access to care did not report or
analyze data by race/ethnicity, income, education, or
community.20 A similar problem with data collection in
part delayed the recognition that COVID-19 was dispro-
portionately harming African Americans and Hispanic/
Latinos.5 In-depth exploration of the social determinants
of health that are the underlying drivers of disparate out-
comes are needed,6 and such data need to be publicly
available to allow clinicians, policy makers, public health
professionals, and policy makers to make informed deci-
sions to better care for these marginalized groups within
the broader HNC population. These steps will indeed
require investment of time and resources; but the absence
of data does not imply the absence of a problem.
3.2 | Raise awareness that racial and
ethnic disparities exist
We should be proactive in recognizing the potential for
exacerbating disparities in access and outcomes during
this massive upheaval of clinical care. Raising awareness
at individual, team, and hospital administrative levels
will be key to ensuring that a broad range of stakeholders
can be brought together and can combine their collective
areas of expertise to proactively seek out, identify, and
address areas of concern. As clinicians and team leaders,
we share responsibility for drawing attention to this prob-
lem and addressing it.
3.3 | Engage communities and
stakeholders to understand their
challenges and develop culturally
appropriate solutions
We also need to reach out to the African American, His-
panic/Latino, and other at-risk communities to better
understand the specific challenges they are facing during
this crisis. Although publications from reputable institu-
tions describing their experiences altering HNC care
delivery during times of crisis may also inform current
solutions,33 it would be presumptuous and ineffective for
clinicians or administrators to pre-suppose that they
already know how to address the problem. Building a
strong coalition of involved stakeholders will help ensure
that whatever health care delivery interventions arise will
be delivered in a manner that is culturally appropriate,
community competent, and relevant to the needs of the
more vulnerable populations. Furthermore, such a coali-
tion will enable us to also look beyond health care ser-
vices into improving community support systems and
policy-level solutions, which can have significant influ-
ences on individual health outcomes.34,35
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3.4 | Ensure that surgical care
prioritization protocols proactively address
the potential for racial/ethnic bias
We should develop and utilize measures that acknowl-
edge the role that racial/ethnic implicit or explicit bias
can play in prioritizing surgical cases. Although the con-
tent and underlying ethical principles of these prioritiza-
tion decision-aids could vary, the role of race and
ethnicity will have to be carefully considered. Although
omitting race/ethnicity data in prioritization may give
the sense of a “color-blind” approach, clinical stage and
severity of comorbidity would likely be part of a prioriti-
zation scheme,28 particularly if one of the guiding ethical
principles is maximizing benefit (eg, life-years).36 How-
ever, African American and Hispanic patients are signifi-
cantly more likely to present with advanced-stage disease
and have more severe comorbidities. Therefore, a “color-
blind” prioritization system based on maximizing benefit
that includes comorbidity and stage may systematically
de-prioritize care for African American and Hispanic/
Latino patients with HNC. Although it might be inappro-
priate to eliminate use of stage or comorbidity, one could
consider incorporating race/ethnicity into prioritization
schemes with an evidence-based, data-driven weight,
determined by relative patient populations and local or
regional prevalence of HNC so as to avoid building
implicit racial bias into prioritization schemes.27 Alterna-
tively, developing a prioritization framework based on
different ethical principles (eg, giving priority to the
worst off)36 might actually prioritize racial/ethnic minori-
ties. Although the details of the optimal solution are not
known, there is a critical need to establish objective mea-
sures and metric-based interventions to diminish current
disparities in the receipt of HNC care. Such a solution
would likely be consistent with the recommendation
from the World Health Organization that the process of
surgical prioritization adhere to principles of inclusive-
ness, transparency, accountability, and consistency.37
4 | CONCLUSION
Although COVID-19 pandemic may eventually dissipate,
health care disparities will likely persist. The COVID-19
pandemic has provided us with a lens, opportunity, and
rationale for renewed dedication to investigating the cau-
ses of and solutions for racial/ethnic disparities in access
and outcomes for patients with HNC. Although many
factors contribute to racial/ethnic disparities in morbidity
and mortality in patients with HNC, health care delivery
should not be one of them.
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